Otonomy, Inc. – NASDAQ:OTIC

Add to watchlist

$0.11

+0.10

+1193.53%

Market closed

Open in 2 days

-91.70%

month

-88.31%

quarter

-99.59%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.01
EV/Sales	-515.43
EV/EBITDA	1.29
Price/Sales	4.65
Price/Book	N/A
PEG ratio	N/A
EPS	-0.79

Revenue	N/A
EBITDA	-50.2M
Income	-52.98M
Revenue Q/Q	N/A
Revenue Y/Y	-100%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Otonomy, Inc. (NASDAQ:OTIC): Profit margin
Dec 2021	0	-13.37M
Mar 2022	0	-13.95M
Jun 2022	0	-13.40M
Sep 2022	0	-12.25M

Otonomy, Inc. (NASDAQ:OTIC): Debt to assets
Dec 2021	95637000	40.73M	42.59%
Mar 2022	81232000	37.98M	46.76%
Jun 2022	70760000	38.68M	54.67%
Sep 2022	57527000	36.13M	62.81%

Otonomy, Inc. (NASDAQ:OTIC): Cash Flow
Dec 2021	-9.76M	5.24M	91K
Mar 2022	-14.34M	-194K	0
Jun 2022	-9.64M	-194K	115K
Sep 2022	-13.01M	10K	0

Otonomy alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Otonomy, Inc. (NASDAQ:OTIC): Employee count
Aug 2023	51
Sep 2023	51
Oct 2023	51
Nov 2023	51
Dec 2023	51
Jan 2024	51
Feb 2024	51
Mar 2024	51
Apr 2024	51
May 2024	51
Jun 2024	51
Jul 2024	51

Otonomy, Inc. (NASDAQ:OTIC): Insider trades (number of shares)
Period	Buy	Sel
Mar 2022	0	38993
Nov 2022	0	42242

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	28 Nov 2022	CAPPS VICKIE L director director	Common Stock	42,242	$0.1	$4,351
Sale	28 Mar 2022	SAVEL ROBERT MICHAEL II officer: Chief Te..	Common Stock	3,325	$2.41	$8,023
Sale	28 Mar 2022	WEBER DAVID ALLEN director, officer..	Common Stock	11,243	$2.41	$27,129
Sale	28 Mar 2022	CAYER PAUL E officer: Ch. Fina..	Common Stock	5,624	$2.41	$13,571
Sale	28 Mar 2022	FOSTER ALAN CHARLES officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	2,559	$2.41	$6,175
Sale	25 Mar 2022	SAVEL ROBERT MICHAEL II officer: Chief Te..	Common Stock	2,374	$2.39	$5,669
Sale	25 Mar 2022	WEBER DAVID ALLEN director, officer..	Common Stock	8,026	$2.39	$19,166
Sale	25 Mar 2022	CAYER PAUL E officer: Ch. Fina..	Common Stock	4,015	$2.39	$9,588
Sale	25 Mar 2022	FOSTER ALAN CHARLES officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	1,827	$2.39	$4,363
Sale	3 Mar 2021	LICHTER JAY director	Common Stock	207,245	N/A	N/A

Status	Patent	Filling date	Issue date
Application	Application AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS Filling date: 18 Aug 2021 Issue date: 10 Feb 2022	18 Aug 2021	10 Feb 2022
Application	Application AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS Filling date: 18 Aug 2021 Issue date: 10 Feb 2022	18 Aug 2021	10 Feb 2022
Application	Application OTIC GEL FORMULATIONS FOR TREATING OTITIS EXTERNA Filling date: 17 Jun 2021 Issue date: 23 Dec 2021	17 Jun 2021	23 Dec 2021
Grant	Grant Utility: Auris formulations for treating otic diseases and conditions Filling date: 19 Mar 2020 Issue date: 21 Sep 2021	19 Mar 2020	21 Sep 2021
Grant	Grant Utility: Auris formulations for treating OTIC diseases and conditions Filling date: 19 Apr 2019 Issue date: 21 Sep 2021	19 Apr 2019	21 Sep 2021
Application	Application CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS Filling date: 12 Jan 2021 Issue date: 22 Jul 2021	12 Jan 2021	22 Jul 2021
Application	Application OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY Filling date: 25 Apr 2019 Issue date: 24 Jun 2021	25 Apr 2019	24 Jun 2021
Grant	Grant Utility: Otic gel formulations for treating otitis externa Filling date: 14 Sep 2017 Issue date: 22 Jun 2021	14 Sep 2017	22 Jun 2021
Grant	Grant Utility: Treatment using truncated Trk B and Trk C antagonists Filling date: 20 Jul 2018 Issue date: 15 Jun 2021	20 Jul 2018	15 Jun 2021
Application	Application TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF Filling date: 21 Dec 2018 Issue date: 13 May 2021	21 Dec 2018	13 May 2021

Otonomy
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 25 Jul 2022	Q2 2022 Earnings Call Transcript
Q1 2022 9 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 28 Feb 2022	Q4 2021 Earnings Call Transcript
Q3 2021 10 Nov 2021	Q3 2021 Earnings Call Transcript

OTIC earnings call transcripts

Otonomy
Executives

Insider	Age	Compensation
Dr. David Allen Weber (1960) Pres, Chief Executive Officer & Director	65	$927,090
Mr. Paul E. Cayer (1962) Chief Financial & Bus. Officer	63	$583,460
Mr. Robert Michael Savel II (1968) Chief Technical Officer	57	$521,330
Dr. Jay B. Lichter Ph.D. (1962) Co-Founder & Independent Chairman	63	$71,620

Otonomy
Latest News

Tuesday, 29 November 2022
12:27	Why Is Otonomy (OTIC) Stock Up 97% Today?	InvestorPlace
Tuesday, 15 November 2022
12:22	Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now	PennyStocks
Monday, 24 October 2022
21:21	These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022	24/7 Wall Street
Monday, 25 July 2022
20:18	Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 18 July 2022
07:30	Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update	GlobeNewsWire
Monday, 9 May 2022
22:21	Otonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 2 May 2022
07:30	Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update	GlobeNewsWire
Monday, 4 April 2022
12:23	Otonomy: Hearing Loss And Tinnitus Data In 2022	Seeking Alpha
Monday, 28 February 2022
07:30	Otonomy to Participate in Two Upcoming Investor Conferences	GlobeNewsWire
Thursday, 17 February 2022
07:30	Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update	GlobeNewsWire
Wednesday, 10 November 2021
20:36	Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 12 October 2021
07:30	Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313	GlobeNewsWire
Monday, 27 September 2021
07:30	Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting	GlobeNewsWire
Thursday, 2 September 2021
07:30	Otonomy to Participate in Two Upcoming Investor Conferences	GlobeNewsWire
Thursday, 19 August 2021
07:30	Otonomy Appoints Jill Broadfoot to Board of Directors	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 4 Apr 2022

Otonomy: Hearing Loss And Tinnitus Data In 2022

Frequently Asked Questions (FAQ)

What's the price of Otonomy stock today?

One share of Otonomy stock can currently be purchased for approximately $0.11.
When is Otonomy's next earnings date?

Unfortunately, Otonomy's (OTIC) next earnings date is currently unknown.
Does Otonomy pay dividends?

Yes, Otonomy pays dividends and its trailing 12-month yield is 1294.12% with 0% payout ratio. The last Otonomy stock dividend of undefined was paid on 6 Sep 2025.
What is Otonomy's stock symbol?

Otonomy, Inc. is traded on the NASDAQ under the ticker symbol "OTIC".
What is Otonomy's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Otonomy?

Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Otonomy's key executives?
Otonomy's management team includes the following people:
- Dr. David Allen Weber Pres, Chief Executive Officer & Director(age: 65, pay: $927,090)
- Mr. Paul E. Cayer Chief Financial & Bus. Officer(age: 63, pay: $583,460)
- Mr. Robert Michael Savel II Chief Technical Officer(age: 57, pay: $521,330)
- Dr. Jay B. Lichter Ph.D. Co-Founder & Independent Chairman(age: 63, pay: $71,620)
Is Otonomy founder-led company?

Yes, Otonomy is a company led by its founder Dr. Jay B. Lichter Ph.D..
How many employees does Otonomy have?

As Jul 2024, Otonomy employs 51 workers.
When Otonomy went public?

Otonomy, Inc. is publicly traded company for more then 11 years since IPO on 13 Aug 2014.
What is Otonomy's official website?

The official website for Otonomy is otonomy.com.
Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 Executive Drive, San Diego, CA.
How can i contact Otonomy?

Otonomy's mailing address is 4796 Executive Drive, San Diego, CA and company can be reached via phone at +61 93232200.

Otonomy, Inc.

otonomy.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

+61 93232200

4796 Executive Drive
San Diego, CA 92121

CIK: 0001493566
ISIN: US68906L1052
CUSIP: 68906L105